BioNJ’s 9th Annual BioPartnering Conference, developed with J.P. Morgan and Johnson & Johnson Innovation, took place last Wednesday, May 8, at The Palace at Somerset Park.
| TRENTON, N.J., May 15, 2019 /PRNewswire/ -- BioNJ’s 9th Annual BioPartnering Conference, developed with J.P. Morgan and Johnson & Johnson Innovation, took place last Wednesday, May 8, at The Palace at Somerset Park. It was a record-breaking day with 550 attendees from 17 states and 5 countries, up from 423 attendees in 2018; 32 company presentations; over 400 partnering meetings; provocative sessions led by industry leaders and the introduction of our Institution and Start-up Track -- featuring 16 early stage companies originating from institutions in New Jersey, New York and Pennsylvania.
“We couldn’t be happier with the outcome of last week’s event,” said BioNJ President and CEO Debbie Hart. “The Conference is about growing the ecosystem and partnering to bolster medical innovation. The energy throughout the day as new opportunities and business endeavors were discussed was absolutely palpable. We thank our speakers, sponsors, planning team, judges, company and institution exhibitors and all who attended for making this event such a success.” The event brought together biopharmaceutical executives, investors, academic collaborators and business development professionals for a day of 1:1 partnering meetings, plenary sessions, exhibits and posters, networking and company presentations. Hart added, “We are thrilled to have developed this year’s program in concert with our friends from J.P Morgan and Johnson & Johnson Innovation. The commitment, expertise and thought leadership they provided from throughout their organizations were monumental to the success of this year’s conference.” Company presentation awards were given to Michele Korfin, Chief Operating Officer for Tyme Technologies, Inc. and Michael Nelson, JD, Chief Executive Officer for Intrommune Therapeutics; as well as the best pitch presentation award to John Vito d’Antonio-Bertagnolli, Chief Executive Officer for OculoMotor Technologies -- a spinout from New Jersey Institute of Technology. Presenter profiles can be found here: Registration will open later this week for BioNJ’s New X2 BioCruise, with NewYorkBIO, taking place on Thursday, July 18. Join us for a scenic cruise on the New York Harbor where you’ll enjoy dinner, drinks, music and networking. Visit www.BioNJ.org for BioNJ’s full calendar of events. About BioNJ BioNJ is a trade association of nearly 400 Member companies representing research-based life sciences organizations and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org. Contact:
SOURCE BioNJ |
View original content to download multimedia:
